NASDAQ | TSX: ACB
EDMONTON, AB, May 30, 2023 /PRNewswire/ -- Aurora Europe
GmbH, a subsidiary of Aurora Cannabis Inc. (NASDAQ: ACB) (TSX:
ACB), and Ethypharm are pleased to announce that they have once
again been selected by the French General Directorate of Health
(DGS) as exclusive suppliers of dried medical cannabis flower until
the end of the French trial period. The trial has recently been
extended until March 2024.
"We are delighted to have been selected once again to continue
to supply high quality dried medical cannabis flower to the French
pilot program. Driven by our purpose of opening the world to
cannabis, Aurora continues to work hand-in-hand with government
officials, physicians and pharmacists to reduce stigma and further
develop medical markets throughout Europe," says Dr. Axel Gille, President of Aurora Europe.
Aurora and Ethypharm signed an agreement to serve the French
pilot program, led by the National Agency for the Safety of
Medicines and Health Products (ANSM), in October 2020, leveraging both parties' expertise.
Under the terms of the exclusive partnership, Aurora supplies
medical cannabis, as well as EU GMP (Good Manufacturing Practices)
manufacturing and logistics support. Distribution and
pharmacovigilance activities continue to be handled by Ethypharm
Laboratories, Ethypharm's French sales subsidiary.
Within the framework of the extension of the trial, the DGS
opened a call for tenders to supply medical cannabis in
January 2023. In March, Aurora Europe and Ethypharm were selected to
continue to provide medical cannabis produced according to European
GMP standards to patients included in the study.
As committed partners, Ethypharm and Aurora Europe reaffirm their commitment to
patients and healthcare professionals to improve the status and
accessibility of medical cannabis in Europe.
"By planning to make Aurora's pharmaceutical grade medical
cannabis available in France, we
wish to reinforce our expertise in Central Nervous System
pathologies, and in particular in pain treatment. We are proud to
move forward with the French health authorities and health
professionals in this experimentation which, we hope, will show the
interest of the use of medical cannabis to relieve French patients
from certain symptoms such as pain," says Frederic Arnal, General Manager of Ethypharm
Laboratories.
About Aurora Europe
Aurora Europe, headquartered in
Berlin, Germany, is a subsidiary
of Aurora Cannabis Inc., a global leader in the cannabis industry
serving both medical and consumer markets and dedicated to helping
people improve their lives. Aurora
Europe supplies high-quality medical cannabis products to
patients throughout Europe. Aurora is one of the largest authorised
importers and distributors of medical cannabis in the European
Union & the UK. Aurora Deutschland, part of Aurora Europe GmbH,
is one of three companies licensed to grow medicinal cannabis in
Germany. Since May 2022, Aurora Produktions GmbH has been
producing one ton of medicinal cannabis annually in Leuna,
Saxony-Anhalt. Aurora's internal network of EU GMP facilities
delivers high-quality, premium medical cannabis to patients
worldwide. For more information please
visit www.auroramedicine.com or follow us
on www.linkedin.com/company/aurora-europe.
About Ethypharm
Ethypharm is a European pharmaceutical company specializing in two
areas: Central Nervous System and Hospital Injectable Drugs.
Ethypharm markets its medicines directly in Europe and China, and has partners in North America and the Middle East. The Group employs more than 1,600
people, mainly based in Europe and
China.
Ethypharm works closely with the authorities and healthcare
professionals to ensure the appropriate use of and access to its
medicines for the greatest number of people.
For more information about Ethypharm, visit our
website https://www.ethypharm.fr/ and follow us on
LinkedIn.
Forward Looking
Statements
This news release includes statements containing certain
"forward-looking information" within the meaning of applicable
securities law ("forward-looking statements"). Forward-looking
statements are frequently characterized by words such as "plan",
"continue", "expect", "project", "intend", "believe", "anticipate",
"estimate", "may", "will", "potential", "proposed" and other
similar words, or statements that certain events or conditions
"may" or "will" occur. Forward-looking statements made in this news
release include, but are not limited to, the Company's continued
participation in the French pilot program and duration of the
program, the Company's continued supply of medical cannabis and EU
GMP and logistics support, and the Company's ongoing work with, and
commitment to, patients and healthcare professionals to improve the
status and accessibility of medical cannabis throughout Europe.
These forward-looking statements are only predictions. Forward
looking information or statements contained in this news release
have been developed based on assumptions management considers to be
reasonable. Material factors or assumptions involved in developing
forward-looking statements include, without limitation, publicly
available information from governmental sources as well as from
market research and industry analysis and on assumptions based on
data and knowledge of this industry which the Company believes to
be reasonable. Forward-looking statements are subject to a variety
of risks, uncertainties and other factors that management believes
to be relevant and reasonable in the circumstances and that could
cause actual events, results, level of activity, performance,
prospects, opportunities or achievements to differ materially from
those projected in the forward-looking statements. These risks
include, but are not limited to, the ability to retain key
personnel, the ability to continue investing in infrastructure to
support growth, the ability to obtain financing on acceptable
terms, the continued quality of our products, customer experience
and retention, the development of third party government and
non-government consumer sales channels, management's estimates of
consumer demand in Canada and in
jurisdictions where the Company exports, expectations of future
results and expenses, the risk of successful integration of
acquired business and operations, management's estimation that
SG&A will grow only in proportion of revenue growth, the
ability to expand and maintain distribution capabilities, the
impact of competition, the general impact of financial market
conditions, the yield from cannabis growing operations, product
demand, changes in prices of required commodities, competition, and
the possibility for changes in laws, rules, and regulations in the
industry, epidemics, pandemics or other public health crises,
including COVID-19, and other risks, uncertainties and factors set
out under the heading "Risk Factors" in the Company's annual
information form dated September 20,
2022 (the "AIF") and filed with Canadian securities
regulators available on the Company's issuer profile on SEDAR
at www.sedar.com and filed with and available on the
SEC's website at www.sec.gov. The Company cautions that the
list of risks, uncertainties and other factors described in the AIF
is not exhaustive and other factors could also adversely affect its
results. Readers are urged to consider the risks, uncertainties and
assumptions carefully in evaluating the forward-looking statements
and are cautioned not to place undue reliance on such information.
The Company is under no obligation, and expressly disclaims any
intention or obligation, to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise, except as expressly required by applicable securities
law.
Media contact: Anke Illigen, Senior Manager Communications
Europe, Aurora Europe GmbH, Wilmersdorfer Straße 98/99, 10629
Berlin, M +49 (0) 176 18000 423, T +49 (0)30 9832 1601 0,
anke.illigen@auroramedicine.com, www.auroramedicine.com; Avril
Ponnelle, Group Communication Manager, Ethypharm, 194 Bureaux de la
Colline, 92213 Saint-Cloud Cedex - France, M +33 6 3051 2527,
presse@ethypharm.com, www.ethypharm.com
Logo -
https://mma.prnewswire.com/media/2065462/Aurora_Cannabis_Inc__Aurora_and_Ethypharm_Reaffirm_their_Commitm.jpg
Logo
- https://mma.prnewswire.com/media/2086936/Aurora_Cannabis_Inc__Aurora_and_Ethypharm_Reaffirm_their_Commitm.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/aurora-and-ethypharm-reaffirm-their-commitment-to-promote-access-to-medical-cannabis-for-french-patients-301836178.html